BiotechTube
Home/Pipeline/XmAb®564

XmAb®564

Autoimmune Diseases

PreclinicalActive

Key Facts

Indication
Autoimmune Diseases
Phase
Preclinical
Status
Active
Company
Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

OncologyAutoimmune DisordersInfectious Disease

Other Autoimmune Diseases Drugs

DrugCompanyPhase
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Gavocabtagene autoleucelAstellasPhase 1/2
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial
I&I PortfolioThird Arc BioPre-clinical
Undisclosed Platform ProgramsZag BioPreclinical
E-602Palleon PharmaceuticalsIND-Enabling
DIASPOT Platform ExpansionDIAsource ImmunoAssaysCommercial & Development